Safety study of a new PET imaging drug for cancers
Part of Cancer, Digestive system, Hormones & metabolism, Lungs & breathing, Women’s health & pregnancy clinical trials.
This Phase 1 study tests how safe RAD301 is and how it behaves in the body when given for PET imaging in healthy volunteers and people with certain cancers. It may help doctors learn whether this imaging drug can clearly show cancer areas and be tolerated well.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older and able to sign informed consent
- If you have cancer, you must have confirmed pancreatic or several other listed solid tumors
- You must have had a recent CT or MRI (within 12 weeks) showing at least one new or remaining disease site
- Recent blood tests must fall within safety ranges (white cells, platelets, hemoglobin, and liver/kidney tests)
- Your oxygen level must be at least 95% while breathing room air, and your ECG timing must be in safe ranges
- You must be willing to follow study rules (no certain drugs before PET, and no donating blood for 4 weeks)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two new radioactive imaging scans (called PET scans) designed to better detect certain advanced cancers like pancreatic, lung, breast, colon, or soft-tissue tumors. The goal is to see if these scans help doctors find and track cancer more accurately than standard imaging.
This study tests a new imaging agent called CM500 that may help doctors see tumors in the body using PET scans. If you are healthy or have cancer, you might be able to join to help find out how well this imaging works.
This trial tests a new radioactive drug (177Lu-NNS309) for people with advanced pancreatic, lung, breast, or colorectal cancer that has not responded to prior treatments. It aims to see if the drug can target and shrink tumors.
This trial tests a new radioactive drug called [177Lu]Lu-DFC413 for people with certain advanced solid tumors that have stopped responding to standard treatments. The drug is designed to target cancer cells with a specific marker seen on a special scan.
This Phase 1 trial tests a new imaging agent (a radioactive tracer) that helps doctors see pancreatic cancer that has spread or cannot be removed by surgery. The scan uses positron emission tomography (PET), a type of imaging that detects cancer cells.
This early-phase study tests a new imaging agent that may help see certain solid tumors (like brain cancer or pancreatic cancer) more clearly. You will receive a single injection of a radioactive tracer, then have several scans over a few days to see where the tracer goes and how long it stays.
Hear when a new Pancreatic Ductal Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.